Spero Therapeutics (SPRO) Stock Price, News & Analysis

Company Overview

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious bacterial infections and other infectious diseases. The company’s research programs are aimed at addressing drug-resistant pathogens and conditions for which existing therapies may be limited.

Spero’s pipeline has included tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic being developed for complicated urinary tract infections, including pyelonephritis. The company has also developed SPR720, an oral antibiotic candidate intended for the treatment of nontuberculous mycobacterial pulmonary disease, and SPR206, an intravenous antibiotic candidate targeting serious infections caused by multidrug-resistant Gram-negative bacteria.

Founded in 2013 and headquartered in Cambridge, Massachusetts, Spero conducts its development activities primarily through clinical research and collaborations with industry and research partners. Its programs are designed for patients in the United States and other markets where resistant bacterial infections and difficult-to-treat infectious diseases represent significant healthcare challenges.

Key Stats

• Today's Range: $1.11 to $1.17
• 50-Day Range: $1.11 to $1.36
• 52-Week Range: $1.08 to $3.08
• Volume: 696,473 shs
• Average Volume: 911,724 shs
• Market Capitalization: $65.22 million
• P/E Ratio: 10.18
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Spero Therapeutics Stock Analysis - MarketRank™

Spero Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 113th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Spero Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and no sell ratings.

Upside Potential

Spero Therapeutics has a consensus price target of $6.00, representing about 435.7% upside from its current price of $1.12.

Amount of Analyst Coverage

Spero Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Spero Therapeutics are expected to decrease in the coming year, from ($0.58) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spero Therapeutics is 10.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.69.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spero Therapeutics is 10.45, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 193.91.

Price to Book Value per Share Ratio

Spero Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.41% of the float of Spero Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Spero Therapeutics has a short interest ratio ("days to cover") of 0.69, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spero Therapeutics has recently decreased by 18.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spero Therapeutics does not currently pay a dividend.

Dividend Growth

Spero Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.86

News Sentiment

Spero Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Spero Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spero Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.90% of the stock of Spero Therapeutics is held by insiders.

Percentage Held by Institutions

25.60% of the stock of Spero Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SPRO
• CIK: 1701108
• Web: sperotherapeutics.com
• Phone: (857) 242-1600
• Fax: N/A
• Employees: 25
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Spero Therapeutics: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +435.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.11
• Trailing P/E Ratio: 10.18
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $8.57 million
• Net Margins: 24.90%
• Pretax Margin: 16.26%
• Return on Equity: 16.17%
• Return on Assets: 12.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.12
• Quick Ratio: 6.12

Sales & Book Value

• Annual Sales: $42.96 million
• Price / Sales: 1.52
• Cash Flow: $0.15 per share
• Price / Cash Flow: 7.56
• Book Value: $1.05 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 58,235,000
• Free Float: 56,546,000
• Market Cap: $65.22 million
• Optionable: Optionable
• Beta: 1.50